Clinical Trials Logo

Clinical Trial Summary

Study evaluating SOM230 in patients with metastatic carcinoid tumors


Clinical Trial Description

n/a


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00088595
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 2
Start date January 2004
Completion date July 2008

See also
  Status Clinical Trial Phase
Completed NCT02441062 - Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors Phase 2
Completed NCT00580320 - Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma Phase 1
Completed NCT02575300 - Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Phase 2
Active, not recruiting NCT02441088 - Theranostics: 68GaDOTATOC and 90YDOTATOC Phase 2
Terminated NCT00227136 - Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion Phase 3
Terminated NCT00947167 - A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors Phase 2
Terminated NCT02177773 - GA-68 DOTA-TOC of Somatostatin Positive Malignancies Phase 1/Phase 2
Active, not recruiting NCT02795858 - A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors Phase 2
Terminated NCT02859064 - Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres Phase 2
Active, not recruiting NCT01731925 - A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors Phase 2
Completed NCT01619865 - Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors Phase 1/Phase 2
Completed NCT01253161 - Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) Phase 2
Terminated NCT02359500 - 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs) Phase 1
No longer available NCT01980732 - 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors N/A
Not yet recruiting NCT01373736 - 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Phase 3